


## NLRP3-IN-32

Cat. No.:	HY-161329
Molecular Formula:	C <sub>21</sub> H <sub>22</sub> BrN <sub>3</sub> O
Molecular Weight:	412.32
Target:	NOD-like Receptor (NLR); NF-κB; Reactive Oxygen Species; IKK
Pathway:	Immunology/Inflammation; NF-κB; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLRP3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation of IκBα and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting NF-κB signaling <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	NLRP3 inflammasome	p65
<b>In Vitro</b>	<p>NLRP3-IN-32 (compound 7a; 1.5, 3, 6 μM) can reverse the release of macrophage inflammatory factors TNF-α, IL-6, IL-18 and IL-1β under LPS (HY-D1056) stimulation in a dose-dependent manner in RAW246.7 cells<sup>[1]</sup>.</p> <p>NLRP3-IN-32 (1.5, 3, 6 μM) inhibits the activation of NLRP3 inflammatory vesicles by dose-dependently scavenging intracellular ROS and NO production by LPS<sup>[1]</sup>.</p> <p>NLRP3-IN-32 (1.5, 3, 6 μM) has low toxicity to RAW246.7 cells and has the apoptosis rates of 3.8%, 5.6%, and 6.8%, respectively<sup>[1]</sup>.</p> <p>NLRP3-IN-32 (1.5, 3, 6 μM; 24 h) shows the dose-dependent inhibition on the phosphorylation of IκBα and p65 phosphorylation levels stimulated with LPS (1.0 μg/mL; 2h) to inhibit NF-κB signaling pathway activation<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

### REFERENCES

[1]. Wen-Xuan Li, et al. Discovery of anti-inflammatory agents from 3, 4-dihydronaphthalene-1(2H)-one derivatives by inhibiting NLRP3 inflammasome activation. Eur J Med Chem. 2024 Feb 29;268:116284.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA